New Collaboration to Enhance Personalized Cancer Drug Development

May 2012, Vol 3, No 3

Genomic Health announced it has formed an alliance with OncoMed Pharmaceuticals to support the development of DNA-sequencing technologies in the search for diagnostic biomarkers that could identify patients who will best benefit from targeted drugs currently in development by OncoMed. These drugs are designed to block specific pathways believed to play a role in cancer-cell growth after chemotherapy.

“Working with like-minded, innovative cancer companies, we can utilize our proven next-generation sequencing-based diagnostic research and development infrastructure to help optimize patient selection to accelerate clinical development of targeted cancer treatments,” said Steven Shak, Genomic Health’s chief medical officer. “This collaboration supports our long-term vision and belief that molecular diagnostics are inherent for bringing quality, personalized care to all cancer patients.”

Paul Hastings, OncoMed’s CEO, noted, “We believe the collaboration with Genomic Health will accelerate our already existing efforts of developing predictive biomarkers alongside the development of our anticancer stem-cell therapies.” Genomic Health, May 2, 2012.

Related Articles